vs
NAPCO SECURITY TECHNOLOGIES, INC（NSSC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
NAPCO SECURITY TECHNOLOGIES, INC的季度营收约是REGENXBIO Inc.的1.6倍（$48.2M vs $30.3M），NAPCO SECURITY TECHNOLOGIES, INC净利率更高（28.0% vs -221.3%，领先249.4%），REGENXBIO Inc.同比增速更快（43.0% vs 12.2%），NAPCO SECURITY TECHNOLOGIES, INC自由现金流更多（$14.5M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -1.1%）
纳普科安全技术公司1969年成立，总部位于纽约阿米蒂维尔，核心业务为研发生产各类安全产品，包括电子锁具、安防警报系统以及楼宇出入管控系统，曾用名纳普科安全系统公司。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
NSSC vs RGNX — 直观对比
营收规模更大
NSSC
是对方的1.6倍
$30.3M
营收增速更快
RGNX
高出30.8%
12.2%
净利率更高
NSSC
高出249.4%
-221.3%
自由现金流更多
NSSC
多$67.3M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-1.1%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $48.2M | $30.3M |
| 净利润 | $13.5M | $-67.1M |
| 毛利率 | 58.6% | — |
| 营业利润率 | 30.6% | -190.0% |
| 净利率 | 28.0% | -221.3% |
| 营收同比 | 12.2% | 43.0% |
| 净利润同比 | 29.0% | -31.2% |
| 每股收益（稀释后） | $0.38 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NSSCRGNX
| Q4 25 | $48.2M | $30.3M | ||
| Q3 25 | $49.2M | $29.7M | ||
| Q2 25 | $50.7M | $21.4M | ||
| Q1 25 | $44.0M | $89.0M | ||
| Q4 24 | $42.9M | $21.2M | ||
| Q3 24 | $44.0M | $24.2M | ||
| Q2 24 | $50.3M | $22.3M | ||
| Q1 24 | $49.3M | $15.6M |
净利润NSSCRGNX
| Q4 25 | $13.5M | $-67.1M | ||
| Q3 25 | $12.2M | $-61.9M | ||
| Q2 25 | $11.6M | $-70.9M | ||
| Q1 25 | $10.1M | $6.1M | ||
| Q4 24 | $10.5M | $-51.2M | ||
| Q3 24 | $11.2M | $-59.6M | ||
| Q2 24 | $13.5M | $-53.0M | ||
| Q1 24 | $13.2M | $-63.3M |
毛利率NSSCRGNX
| Q4 25 | 58.6% | — | ||
| Q3 25 | 56.6% | — | ||
| Q2 25 | 52.8% | — | ||
| Q1 25 | 57.2% | — | ||
| Q4 24 | 57.0% | 70.2% | ||
| Q3 24 | 55.9% | 48.8% | ||
| Q2 24 | 55.3% | 52.5% | ||
| Q1 24 | 53.8% | 72.6% |
营业利润率NSSCRGNX
| Q4 25 | 30.6% | -190.0% | ||
| Q3 25 | 27.7% | -176.3% | ||
| Q2 25 | 23.8% | -296.3% | ||
| Q1 25 | 25.4% | 13.6% | ||
| Q4 24 | 26.0% | -242.1% | ||
| Q3 24 | 26.9% | -256.6% | ||
| Q2 24 | 27.7% | -251.3% | ||
| Q1 24 | 29.4% | -408.8% |
净利率NSSCRGNX
| Q4 25 | 28.0% | -221.3% | ||
| Q3 25 | 24.7% | -208.3% | ||
| Q2 25 | 22.9% | -331.8% | ||
| Q1 25 | 23.0% | 6.8% | ||
| Q4 24 | 24.4% | -241.3% | ||
| Q3 24 | 25.4% | -246.3% | ||
| Q2 24 | 26.9% | -237.7% | ||
| Q1 24 | 26.8% | -405.4% |
每股收益（稀释后）NSSCRGNX
| Q4 25 | $0.38 | $-1.30 | ||
| Q3 25 | $0.34 | $-1.20 | ||
| Q2 25 | $0.33 | $-1.38 | ||
| Q1 25 | $0.28 | $0.12 | ||
| Q4 24 | $0.28 | $-0.99 | ||
| Q3 24 | $0.30 | $-1.17 | ||
| Q2 24 | $0.36 | $-1.05 | ||
| Q1 24 | $0.36 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $115.4M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $184.8M | $102.7M |
| 总资产 | $212.8M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NSSCRGNX
| Q4 25 | $115.4M | $230.1M | ||
| Q3 25 | $105.8M | $274.2M | ||
| Q2 25 | $99.2M | $323.3M | ||
| Q1 25 | $89.3M | $267.9M | ||
| Q4 24 | $99.2M | $234.7M | ||
| Q3 24 | $91.3M | $255.5M | ||
| Q2 24 | $70.7M | $290.4M | ||
| Q1 24 | $60.9M | $338.7M |
股东权益NSSCRGNX
| Q4 25 | $184.8M | $102.7M | ||
| Q3 25 | $176.1M | $161.5M | ||
| Q2 25 | $168.6M | $213.7M | ||
| Q1 25 | $161.5M | $274.2M | ||
| Q4 24 | $174.2M | $259.7M | ||
| Q3 24 | $178.6M | $301.4M | ||
| Q2 24 | $178.9M | $348.3M | ||
| Q1 24 | $168.2M | $390.7M |
总资产NSSCRGNX
| Q4 25 | $212.8M | $453.0M | ||
| Q3 25 | $206.0M | $525.2M | ||
| Q2 25 | $198.1M | $581.0M | ||
| Q1 25 | $190.9M | $490.9M | ||
| Q4 24 | $202.7M | $466.0M | ||
| Q3 24 | $209.9M | $519.1M | ||
| Q2 24 | $207.8M | $569.4M | ||
| Q1 24 | $194.8M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $15.1M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $14.5M | $-52.8M |
| 自由现金流率自由现金流/营收 | 30.1% | -174.0% |
| 资本支出强度资本支出/营收 | 1.2% | 1.7% |
| 现金转化率经营现金流/净利润 | 1.12× | — |
| 过去12个月自由现金流最近4个季度 | $53.7M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流NSSCRGNX
| Q4 25 | $15.1M | $-52.3M | ||
| Q3 25 | $11.6M | $-56.0M | ||
| Q2 25 | $14.6M | $-49.3M | ||
| Q1 25 | $13.4M | $33.6M | ||
| Q4 24 | $13.5M | $-31.6M | ||
| Q3 24 | $12.0M | $-40.5M | ||
| Q2 24 | $14.3M | $-45.5M | ||
| Q1 24 | $12.3M | $-55.5M |
自由现金流NSSCRGNX
| Q4 25 | $14.5M | $-52.8M | ||
| Q3 25 | $11.4M | $-56.5M | ||
| Q2 25 | $14.4M | $-49.7M | ||
| Q1 25 | $13.3M | $32.6M | ||
| Q4 24 | $12.4M | $-32.7M | ||
| Q3 24 | $11.3M | $-40.9M | ||
| Q2 24 | $13.8M | $-46.0M | ||
| Q1 24 | $12.0M | $-56.0M |
自由现金流率NSSCRGNX
| Q4 25 | 30.1% | -174.0% | ||
| Q3 25 | 23.3% | -189.9% | ||
| Q2 25 | 28.4% | -232.8% | ||
| Q1 25 | 30.3% | 36.6% | ||
| Q4 24 | 28.8% | -154.2% | ||
| Q3 24 | 25.8% | -168.9% | ||
| Q2 24 | 27.4% | -206.2% | ||
| Q1 24 | 24.3% | -358.5% |
资本支出强度NSSCRGNX
| Q4 25 | 1.2% | 1.7% | ||
| Q3 25 | 0.4% | 1.7% | ||
| Q2 25 | 0.5% | 1.8% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | 2.6% | 5.1% | ||
| Q3 24 | 1.5% | 1.3% | ||
| Q2 24 | 1.1% | 2.1% | ||
| Q1 24 | 0.7% | 3.6% |
现金转化率NSSCRGNX
| Q4 25 | 1.12× | — | ||
| Q3 25 | 0.96× | — | ||
| Q2 25 | 1.26× | — | ||
| Q1 25 | 1.32× | 5.53× | ||
| Q4 24 | 1.29× | — | ||
| Q3 24 | 1.08× | — | ||
| Q2 24 | 1.06× | — | ||
| Q1 24 | 0.94× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NSSC
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
